NCT00841477View on ClinicalTrials.gov

An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users

PHASE3CompletedINTERVENTIONAL
Enrollment

1,260

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

December 31, 2009

Conditions
Hepatitis B InfectionHepatitis C InfectionHIV Infection
Interventions
BIOLOGICAL

hepatitis B vaccine 3 dose schedule (0,1,2 month)

hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)

BEHAVIORAL

HBV Vaccination Self-Efficacy Intervention

HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose

Trial Locations (1)

77030

University of Texas-HSC at Houston, School of Public Health, Houston

All Listed Sponsors
lead

National Institute on Drug Abuse (NIDA)

NIH

NCT00841477 - An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users | Biotech Hunter | Biotech Hunter